#ASCO26: Merck Partner Kelun Outlines Phase 3 Lung Cancer Success in China Study

Why It Matters

The trial’s success could add a high‑value oncology asset to Merck’s pipeline and accelerate its presence in China’s fast‑growing cancer market. A positive outcome also validates the antibody‑drug conjugate platform for lung cancer, influencing competitive dynamics worldwide.

Key Takeaways

• Phase 3 sac‑TMT trial met overall survival and PFS endpoints
• Study enrolled over 600 Chinese NSCLC patients across 30 sites
• Merck aims to seek Chinese regulatory approval by year‑end
• Success strengthens Merck‑Kelun partnership and ADC pipeline
• Results may prompt global filing and reshape lung‑cancer treatment landscape

Pulse Analysis

The Phase 3 data for sac‑TMT, an antibody‑drug conjugate targeting a tumor‑specific antigen, represent a milestone for both Merck and its Chinese collaborator Kelun‑Biotech. ADCs combine the precision of monoclonal antibodies with potent cytotoxic payloads, and sac‑TMT’s survival advantage in a large, diverse Chinese cohort underscores the therapeutic promise of this technology. By delivering the results at ASCO 2026, the partners signal confidence in the robustness of the trial design and its relevance to global oncology standards.

For Merck, the positive readout bolsters a portfolio that already includes blockbuster immunotherapies such as Keytruda. Adding an ADC with proven efficacy in non‑small cell lung cancer diversifies its late‑stage pipeline and offers a differentiated option for patients who have progressed on existing regimens. The Chinese market, now the world’s second‑largest for oncology drugs, provides a rapid path to revenue, and a successful local filing could generate significant sales before a potential U.S. or EU submission. Competitors developing lung‑cancer ADCs will need to reassess timelines as Merck leverages its scale and manufacturing expertise.

Industry observers view the Kelun‑Biotech collaboration as a template for multinational drug development in China, where regulatory reforms have streamlined trial approvals. The success of sac‑TMT may encourage more Western biotech firms to partner with Chinese innovators, tapping into large patient pools and cost‑effective research infrastructure. As ADCs continue to gain traction across multiple cancer indications, this breakthrough could accelerate investment in next‑generation conjugates, shaping the future competitive landscape of precision oncology.